Publication:
Rivaroxaban for the treatment of saphenous vein graft thrombosis

Placeholder

Departments

OrgUnit Logo
Organizational Unit

School / College / Institute

OrgUnit Logo
Organizational Unit
SCHOOL OF MEDICINE
Upper Org Unit

Program

KU-Authors

KU Authors

Co-Authors

Marmagkiolis, Konstantinos

Editor & Affiliation

Compiler & Affiliation

Translator

Other Contributor

Date

2016

Language

Type

Journal Article

Embargo Status

N/A

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Thrombus formafigtion plays a significant role in disease of saphenous vein bypass grafts. Use of oral anticoagulants has not been tested in treatment of thrombotic occlusion of saphenous vein graft (SVG) disease. Here we describe the use of the novel oral anticoagulant rivaroxaban in the treatment of occlusive SVG disease with intraluminal thrombus, leading to successful recanalization. (C) 2016 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved.

Source

Publisher

Elsevier Doyma Sl

Subject

Cardiac, Cardiovascular systems

Citation

Has Part

Source

Revista Portuguesa De Cardiologia

Book Series Title

Edition

DOI

10.1016/j.repc.2015.11.024

URI

https://doi.org/10.1016/j.repc.2015.11.024
 https://hdl.handle.net/20.500.14288/12809

item.page.datauri

Link

Rights

N/A

Copyrights Note

Collections

Publications without Fulltext

Endorsement

Review

Supplemented By

Referenced By

Related Goal

Thumbnail Image
GoalOpen Access
03 - Good Health and Well-being
Over the last 15 years, the number of childhood deaths has been cut in half. This proves that it is possible to win the fight against almost every disease. Still, we are spending an astonishing amount of money and resources on treating illnesses that are surprisingly easy to prevent. The new goal for worldwide Good Health promotes healthy lifestyles, preventive measures and modern, efficient healthcare for everyone.

0

Views

0

Downloads

View PlumX Details